Fluorescence in situ hybridization monitoring of BCR-ABL-positive neutrophils in chronic-phase chronic myeloid leukemia patients during the primary stage of imatinib mesylate therapy

International Journal of Hematology

Volumn 81, Issue 3, 2005, Pages 235-241

  Takahashi, Naoto ^a,b   Miura, Ikuo ^b   Kobayashi, Yoshimi ^b   Kume, Masaaki ^b   Yoshioka, Tomoko ^b   Otane, Wataru ^c   Ohtsubo, Kaori ^d   Takahashi, Kaoru ^e   Kitabayashi, Atsushi ^f   Kawabata, Yoshinari ^b   Hirokawa, Makoto ^b   Nishijima, Hirokazu ^d   Ichinohasama, Ryo ^g   DeCoteau, John ^a   Miura, Akira B ^h   Sawada, Ken Ichi ^b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c BML   (Japan)

^d SRL INC   (Japan)

^e The Japanese Red Cross Junior College of Akita   (Japan)

^f Akita Kumiai General Hospital   (Japan)

^g TOHOKU UNIVERSITY   (Japan)

^h AKITA UNIVERSITY   (Japan)

Author keywords

BCR ABL; Chronic myeloid leukemia (CML); Fluorescence in situ hybridization (FISH); Imatinib mesylate (Glivec, Gleevec); Neutrophils

Indexed keywords

HYDROXYUREA; IMATINIB; INTERFERON; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; BCR ABL GENE; BONE MARROW CELL; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; DRUG RESPONSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE FUSION; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; INTERPHASE; MALE; METAPHASE; NEUTROPHIL; NEUTROPHIL FLUORESCENCE IN SITU HYBRIDIZATION; PATIENT MONITORING; PERIPHERAL BLOOD MONONUCLEAR CELL; PHILADELPHIA 1 CHROMOSOME; REAL TIME POLYMERASE CHAIN REACTION; REAL TIME REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TECHNIQUE; BIOSYNTHESIS; CLINICAL TRIAL; IN SITU HYBRIDIZATION; METABOLISM; METHODOLOGY; MONITORING; MYELOID LEUKEMIA; PATHOLOGY; PATHOPHYSIOLOGY;

ANTINEOPLASTIC AGENTS; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; IN SITU HYBRIDIZATION; LEUKEMIA, MYELOID, CHRONIC-PHASE; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MONITORING, PHYSIOLOGIC; NEUTROPHILS; PIPERAZINES; PYRIMIDINES;

EID: 20344399890     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.04095     Document Type: Article

References (31)

1. O'Brien SG, Guilhot F, Larson RA, et al, for the IRIS Investigators. Imatinib compared with Interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
2. Kantarjian H, Sawyer C, Hochhaus A, et al, for the International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
3. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102:276-283.
4. Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 1998;338:962-968.
5. Gratwohl A, Hermans J, Goldmon JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation: Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;352:1087-1092.
6. Talpaz M, Kantarjian HM, Kurzrock R, Trujillo JM, Gutterman JU. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia: Philadelphia chromosome-positive patients. Ann Intern Med. 1991;114:532-538.
7. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Long-term follow-up of the Italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. Blood. 1998;92:1541-1548.
8. Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003;21:1637-1647.
9. Miura I, Takahashi N, Kobayashi Y, Saito K, Miura AB. Molecular cytogenetics of stem cells: target cells of chromosome aberrations as revealed by the application of fluorescence in situ hybridization to fluorescence- activated cell sorting. Int J Hematol. 2000;72:310-317.
10. Muhlmann J, Thaler J, Hilbe W, et al. Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission assessment. Genes Chromosomes Cancer. 1998;21:90-100.
11. Le Gouill S, Talmant P, Milpied N, et al. Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia. J Clin Oncol. 2000;18:1533-1538.
12. Lee YK, Lee DW, Kim YL, et al. Detection of the BCR-ABL gene by interphase fluorescence in situ hybridization (iFISH) in chronic myelogenous leukemia patients after hemopoietic stem cell transplantation: the feasibility of iFISH monitoring of therapeutic response in peripheral blood. Int J Hematol. 2002;76:180-185.
13. Buno I, Wyatt WA, Zinsmeister AR, Dietz-Band J, Silver RT, Dewald GW. A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia. Blood. 1998;92:2315-2321.
14. Cuneo A, Bigoni R, Emmanuel B, et al. Fluorescence in situ hybridization for the detection and monitoring of the Ph-positive clone in chronic myelogenous leukemia: comparison with metaphase banding analysis. Leukemia. 1998;12:1718-1723.
15. Yanagi M, Shinjo K, Takeshita A, et al. Simple and reliably sensitive diagnosis and monitoring of Philadelphia chromosome-positive cells in chronic myeloid leukemia by interphase fluorescence in situ hybridization of peripheral blood cells. Leukemia. 1999;13:542-552.
16. Lesser ML, Dewald GW, Sison CP, Silver RT. Correlation of three methods of measuring cytogenetic response in chronic myelocytic leukemia. Cancer Genet Cytogenet. 2002;137:79-84.
17. Akel S, Kolialexi A, Mavrou A, Metaxotou C, Loukopoulos D, Yataganas X. Efficiency of interphase fluorescence in situ hybridization for BCR/ABL on peripheral blood smears for monitoring of CML patients: a comparison with bone marrow findings. Clin Lab Haematol. 2002;24:361-367.
18. Reinhold U, Hennig E, Leiblein S, Niederwieser D, Deininger MWN. FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib. Leukemia. 2003;17:1925-1929.
19. Takahashi N, Miura I, Saitoh K, Miura AB. Lineage involvement of stem cells bearing the Philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization. Blood. 1998;92:4758-4763.
20. Hashimoto K, Miura I, Chubachi A, Saito M, Miura AB. Correlations of chromosome abnormalities with histologic and immunologic characteristics in 49 patients from Akita, Japan with non-Hodgkin lymphoma. Cancer Genet Cytogenet. 1995;81:56-65.
21. Kantarjian HM, Keating MJ, Smith TL, Talpaz M, McCredie KB. Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am J Med. 1990;88:1-8.
22. Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J. Clinical investigation of human alpha Interferon in chronic myelogenous leukemia. Blood. 1987;69:1280-1288.
23. Tefferi A, Schad CR, Pruthi RK, Ahmann GJ, Spurbeck JL, Dewald GW. Fluorescent in situ hybridization studies of lymphocytes and neutrophils in chronic granulocytic leukemia. Cancer Genet Cytogenet. 1995;83:61-64.
24. Lange T, Bumm T, Otto S, et al. Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy. Haematologica. 2004;89:49-57.
25. Kantarjian HM, Talpaz M, Cortes J, et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; Gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res. 2003;9:160-166.
26. Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol. 1999; 107:587-599.
27. Hochhaus A, Reiter A, Saussele S, et al. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood. 2000; 95:62-66.
28. Olavarria E, Kanfer E, Szydlo R, et al. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood. 2001;97:1560-1565.
29. Merx K, Muller MC, Kreil S, et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia. 2002;16:1579-1583.
30. Wang L, Pearson K, Ferguson JE, Clark RE. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol. 2003;120:990-999.
31. Bumm T, Mueller C, Al-Ali HK, et al. Emergence of clonal cytogenetic abnormalities in Ph-negative cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood. 2003;101:1941-1949.